Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02983227 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350
A Phase 2 study, sponsored by Genentech.
- Completed
- Registry status
- Phase 2
- Development phase
- 496
- Enrollment target
NCT02983227 is a Phase 2 study that has completed, run by Genentech. The registered enrollment target is 496 participants.
The verdict
NCT02983227, a Phase 2 study, has completed, sponsored by Genentech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 496 participants
- Enrollment target
Study Summary
A study to evaluate the long-term safety and efficacy of GDC-0853 in participants with moderate to severe active Rheumatoid Arthritis (RA) who have completed 12 weeks of study treatment in Study GA29350. Eligible participants from Study GA29350 who elect to participate will receive treatment with GDC-0853 twice daily (BID) in an open-label fashion for 52 weeks, followed by a safety follow-up period of 8 weeks.
Interventions
- DRUG GDC-0853
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 496 participants |
| Start Date | 2016-11-30 |
| Est. Completion | 2019-07-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02983227
The ClinicalTrials.gov registry entry for NCT02983227 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 496 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genentech, which has 332 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GDC-0853 is the first listed.
NCT02983227 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02983227 about?
NCT02983227 is a clinical study titled "A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350". A study to evaluate the long-term safety and efficacy of GDC-0853 in participants with moderate to severe active Rheumatoid Arthritis (RA) who have completed 12 weeks of study treatment in Study GA29350. Eligible participants from Study GA29350 who elect to participate will receive treatment with GD...
What is the current status of trial NCT02983227?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 496 participants. The study started on 2016-11-30. Estimated completion is 2019-07-17.
What interventions are being tested in trial NCT02983227?
The interventions under investigation include: GDC-0853 (DRUG).
Who is sponsoring clinical trial NCT02983227?
This trial is sponsored by Genentech, which has 332 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.